Publicaciones científicas

Consensus on the Definition of Control and Remission in Chronic Urticaria

22-jul-2022 | Revista: Journal of Investigational Allergology & Clinical Immunology

A M Giménez-Arnau  1 , I Jáuregui  2 , J F Silvestre-Salvador  3 , A Valero  4 , M Ferrer  5 , J Sastre  6 , F J Ortiz de Frutos  7 , M Labrador-Horrillo  8 , J Bartra  4 , J Miquel Miquel  9 , Urticaria Study Group


Abstract

The terms control and remission and other key terms used in chronic urticaria (CU) such as flare-up, relapse, exacerbation, and recurrence have not been fully defined in the literature.

Disease monitoring and treatment goals in clinical practice are not well established. After a qualitative appraisal of available evidence, we aimed to find a consensus definition of control and remission, clarify key terminology, provide guidance on how to monitor the disease, and establish treatment goals in clinical practice.

A modified Delphi consensus approach was used. Based on a literature review, a scientific committee provided 137 statements addressing controversial definitions and terms, available patient-reported outcomes (PROs), and recommendations on how to measure therapeutic objectives in CU.

The questionnaire was evaluated by 138 expert allergists and dermatologists. A consensus was reached on 105 out of the 137 proposed items (76.6%). The experts agreed that complete control and remission of CU could be defined as the absence of signs or symptoms while on treatment and in the absence of treatment, respectively.

Consensus was not reached on the definition of other key terms such as flare-up, exacerbation, and recurrence. The panel agreed that the objective of therapy in CU should be to achieve complete control. PROs that define the degree of control (complete, good, partial, or absence) were established. An algorithm for disease assessment is provided.

In conclusion, this work offers consensus definitions and tools that may be useful in the management of patients with CU.

CITA DEL ARTÍCULO  J Investig Allergol Clin Immunol. 2022 Jul 22;32(4):261-269. doi: 10.18176/jiaci.0820.  Epub 2022 May 3.